Chronological Index of BioCentury, Week in Review: Clinical Results

• Varisolve: Phase III data

  BTG plc (LSE:BGC), London, U.K. Product: Varisolve Business: Cardiovascular Molecular target: Not available Description: Polidocanol endovenous microfoam (PEM) Indication: Treat varicose veins Endpoint: Change from …

  Published on 4/30/2012

• Varisolve: Phase III data

  BTG plc (LSE:BGC), London, U.K. Product: Varisolve Business: Cardiovascular Molecular target: Not available Description: Polidocanol endovenous microfoam (PEM) Indication: Treat varicose veins Endpoint: Change from …

  Published on 4/30/2012

• Vyvanse lisdexamfetamine dimesylate: Phase II data

  Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Product: Vyvanse lisdexamfetamine dimesylate Business: Neurology Molecular target: Not available Description: Prodrug of amphetamine Indication: Treat binge eating …

  Published on 4/30/2012

• Zerenex ferric citrate: Phase III data

  Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), New York, N.Y. Panion & BF Biotech Inc., Taipei, Taiwan Japan Tobacco Inc. (Tokyo:2914; Osaka:2914), Tokyo, Japan Product: Zerenex ferric citrate (JTT-751) Business: …

  Published on 4/30/2012

• ABT-450: Additional Phase II data

  Enanta Pharmaceuticals Inc., Cambridge, Mass. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: ABT-450 Business: Infectious Molecular target: HCV NS3/4A protease complex Description: Oral HCV NS3/4A protease …

  Published on 4/23/2012

• Actemra: Phase III data

  Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Actemra (RoActemra - EU) tocilizumab (RG1569) Business: Autoimmune Molecular target: Interleukin-6 (IL-…

  Published on 4/23/2012

• Alisporivir: Additional Phase IIb data

  Debiopharm Group, Lausanne, Switzerland Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Alisporivir (Debio 025, DEB025) Business: Infectious Molecular target: Cyclophilin Description: Oligopeptide …

  Published on 4/23/2012

• Alisporivir: Development hold

  Debiopharm Group, Lausanne, Switzerland Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Alisporivir (Debio 025, DEB025) Business: Infectious Molecular target: Cyclophilin Description: Oligopeptide …

  Published on 4/23/2012

• Alisporivir: Phase II data

  Debiopharm Group, Lausanne, Switzerland Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Alisporivir (Debio 025, DEB025) Business: Infectious Molecular target: Cyclophilin Description: Oligopeptide …

  Published on 4/23/2012

• Avastin bevacizumab cancer data

  Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Avastin bevacizumab (RG435) Business: Cancer Molecular …

  Published on 4/23/2012

• CG100649: Phase IIb data

  CrystalGenomics Inc. (KOSDAQ:083790), Seongnam, South Korea Product: CG100649 Business: Autoimmune Molecular target: Cyclooxygenase-2 (COX-2); Carbonic anhydrase l (CAI) Description: Dual-acting cyclooxygenase-2 (COX-2)…

  Published on 4/23/2012

• Cimzia certolizumab pegol: Phase III data

  UCB Group (Euronext:UCB), Brussels, Belgium Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Cimzia certolizumab pegol Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: …

  Published on 4/23/2012

• Florbetaben: Phase III data

  Piramal Healthcare Ltd. (BSE:500302; NSE:PIRHEALTH), Mumbai, India Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Florbetaben (BAY 94-9172, ZK 6013443) Business: Diagnostic Molecular target: Beta amyloid …

  Published on 4/23/2012

• Injectafer: Phase IV data

  Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Galenica Ltd. (SIX:GALN), Bern, Switzerland Product: Injectafer (Ferinject - EU) ferric carboxymaltose Business: Hematology Molecular target: Not applicable…

  Published on 4/23/2012

• Kynamro mipomersen: Phase III data

  Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Kynamro mipomersen (ISIS 301012 subcutaneous) Business: Endocrine/Metabolic Molecular target: …

  Published on 4/23/2012

• ONO-4641: Phase II data

  Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528), Osaka, Japan Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: ONO-4641 Business: Autoimmune Molecular target: Sphingosine 1-phosphate (S1P) receptor Description: …

  Published on 4/23/2012

• PSI-7977: Additional Phase IIb data

  Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: PSI-7977, GS-7977 Business: Infectious Molecular target: HCV NS5B polymerase Description: Single isomer form of PSI-7851, a nucleotide analog HCV NS5B …

  Published on 4/23/2012

• PSI-7977: Additional Phase IIb data

  Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: PSI-7977, GS-7977 Business: Infectious Molecular target: HCV NS5B polymerase Description: Single isomer form of PSI-7851, a nucleotide analog HCV NS5B …

  Published on 4/23/2012

• PSI-7977: Interim Phase IIa data

  Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: PSI-7977, GS-7977 Business: Infectious Molecular target: HCV NS5B polymerase Description: Single isomer form of PSI-7851, a nucleotide analog HCV NS5B …

  Published on 4/23/2012

• PSI-7977: Interim Phase IIb data

  Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: PSI-7977, GS-7977 Business: Infectious Molecular target: HCV NS5B polymerase Description: Single isomer form of PSI-7851, a nucleotide analog HCV NS5B …

  Published on 4/23/2012

• PSI-7977: Interim Phase IIb data

  Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: PSI-7977, GS-7977 Business: Infectious Molecular target: HCV NS5B polymerase Description: Single isomer form of PSI-7851, a nucleotide analog HCV NS5B …

  Published on 4/23/2012

• Replagal agalsidase alfa endocrine/metabolic data

  Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506), Osaka, Japan Product: Replagal agalsidase alfa Business: Endocrine/Metabolic Molecular target: Not …

  Published on 4/23/2012

• RHB-102: Final pivotal trial data

  RedHill Biopharma Ltd. (Tel Aviv:RDHL), Ramat-Gan, Israel Scolr Pharma Inc. (OTCBB:SCLRE), Bothell, Wash. Product: RHB-102 Business: Gastrointestinal Molecular target: Serotonin (5-HT3) receptor Description: Once-daily …

  Published on 4/23/2012

• TH-302: Phase IIb data

  Threshold Pharmaceuticals Inc. (NASDAQ:THLD), South San Francisco, Calif. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: TH-302 Business: Cancer Molecular target: Not available Description: Hypoxia-activated …

  Published on 4/23/2012

• TNX-102: Phase I data

  Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP), New York, N.Y. Product: TNX-102 Business: Musculoskeletal Molecular target: Serotonin (5-HT2A) receptor Description: A 2.4 mg promicellar gelatin capsule formulation of …

  Published on 4/23/2012